An interventional study of Self-management education and pain neuroscience education in Fibromyalgia, sponsored by Taipei Medical University. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-11-20.
Sponsored by Taipei Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Fibromyalgia with a site in Taiwan — 4 open to participants now, 4 under way, none of them phase 3. Fibromyalgia · Taiwan.
Among the 12 studies in Fibromyalgia with a site in Taiwan, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 6 with no phase, and was the 11th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →4 of the 12 studies in Fibromyalgia with a site in Taiwan are open now. Recruiting first, the newest first:
Taipei Medical University · Sites in Taiwan
Ages 20–75
Kaohsiung Medical University Chung-Ho Memorial Hospital · Sites in Taiwan
Ages 18–70
Taipei Medical University · Sites in Taiwan
Ages 20–64 · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 98 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 105 across the 11 interventional studies, 245 across the 1 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 12 have an industry lead sponsor. The 7 most frequent:
Taipei Medical University is the lead sponsor of 258 studies on the registry; 59 are open to participants now.
Taipei Medical University has 5 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Fibromyalgia with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized controlled trials study aims, first, to determine the effectiveness of a nurse-led PNE program designed by a multidisciplinary team, compared with an active control group on pain intensity, fibromyalgia (FM) severity, pain catastrophizing, and cognitive performance in patients with FM. Second, to determine the mediator role of pain catastrophizing in the effects of PNE on outcomes of interest. Third, to explore PNE-induced changes to the brain circuitry using QEEG in patients with FM.
This is a parallel-group, randomized controlled trial (RCT). 98 participants who meet the 2016 American College of Rheumatology diagnostic criteria for FM will be enrolled.
Eligible participants who complete the baseline measurements will be randomly allocated to a PNE group (N = 49) and a self-management education group (N = 49).
Primary outcomes include pain severity determined using the Brief Pain Inventory-Short Form (BPI-SF) and FM severity assessed using the Fibromyalgia Impact Questionnaire-Revised (FIQR).
Secondary outcomes, including pain catastrophizing and sustained attention, will examine using the Pain Catastrophizing Scale (PCS), the Psychomotor Vigilance Test (PVT), and QEEG, respectively.
All outcomes will be measured at 3 different time points: (T0: baseline; T1: immediately after the 6-week intervention period; and T2: 3 months after the intervention period).
Implications:
This will be the first-ever RCT to examine the effectiveness of a Chinese-language PNE program and the first study to determine the brain changes after PNE using QEEG in patients with FM. Once the effectiveness of the PNE and its brain mechanisms are supported by evidence from this trial, it will become a game changer in the management of the FM population. If an evidence-based PNE platform based on the patented training course is subsequently developed, the product will have great potential for commercialization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in the control group will receive an SME via weekly video calls over 6 weeks.
Other: Self-management education
Participants in the experimental group will receive a 6-week PNE program.
Behavioral: pain neuroscience education
A self-management of the FM handbook will be provided. SME will be delivered via weekly video calls over a 6-week period. The video call lasting for 15 minutes, will consist of reviewing the weekly self-management content (5 min), questioning and answering related to the content of the self-management handbook (5 min), and a debriefing session (5 min).
Participants in the experimental group will receive a 6-week PNE program. The PNE program that is designed to explain pain to the participants will be implemented via 6 individual face-to-face sessions, each lasting for 45 minutes over a 6-week period. Printed take-home materials will be provided to the participants to enhance learning. The goal of PNE is to increase participants' knowledge about pain to help them reconceptualize their beliefs about pain and decrease perceived threats of pain. The content will be composed according to the second edition of the book, "Explain Pain" by Butler and Mosley (2013) as well as etiologies of fibromyalgia. Accordingly, the PI has developed the preliminary PNE content.
the Brief Pain Inventory-Short Form (BPI-SF)
The BPI-SF evaluates pain in different contexts: worst pain, least pain, average pain, and current pain, rated on a 0-10 scale.
Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.
the Fibromyalgia Impact Questionnaire Revised (FIQR)
The FIQR includes 21 questions involving 3 domains: physical function, overall effect of fibromyalgia, and fibromyalgia symptoms (pain, fatigue, unrefreshing sleep, stiffness, anxiety, depression, tenderness to touch, memory, balance, and environmental sensitivity).
Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.
Pain Catastrophizing Scale(PCS)
The PCS is a self-reported questionnaire consisting of 13 items that assess negative emotional and cognitive processes (e.g., helplessness, rumination, pessimism, and magnification of symptoms).
Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.
Psychomotor Vigilance Test (PVT)
The standard 3-minute PVT will be used in this study to assess sustained or vigilant attention. The PVT is performed by recording the response time to visual stimuli, occurring at random inter stimulus intervals.
Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.
Quantitative electroencephalography
Resting-state EEG measurements with eyes closed will be taken for 10 min using the BrainMaster Discovery 24 EEG device. The participants will be seated with their eyes closed for 20 min before the measurements to achieve this stable/resting state. Five minutes of artifact-free EEG will be used in this study.
Time frame: baseline; T1 = immediately after PNE; T2 = 3th month after intervention.
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Feb 2026, 29 months after the start.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 29 months is above that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.